Palliative Sedation at Home in Patients with Advanced Cancer: A Retrospective Observational Study of Clinical Characteristics and Sedation-Related Outcomes
- 1Grupo de Investigación en Cuidados Paliativos (GRICPAL), Facultad de Medicina y Ciencias de la Salud, Universidad Católica de Valencia “San Vicente Mártir”, c/Espartero 7, 46007 Valencia, Spain
- 2Fundación Instituto Valenciano de Oncología, c/Beltrán Báguena 4, 46009 Valencia, Spain
Abstract
Background/Objectives: Palliative sedation may relieve refractory suffering in patients with advanced cancer receiving end-of-life care at home. We aimed to describe patient characteristics, palliative sedation use, refractory symptoms, and sedation-related outcomes in a specialized hospital-at-home unit. Methods: We conducted a retrospective observational study of patients with advanced cancer who died during 2022 while receiving care from the Instituto Valenciano de Oncología hospital-at-home unit, Spain. Admission required clinical and social assessment confirming the need for hospital-level home care, feasibility of care at home, and adequate caregiver support. Sociodemographic, clinical, and sedation-related data were obtained from medical records. Analyses were descriptive and exploratory; associations were unadjusted. Results: The cohort included 113 patients; 80 (70.8%) received palliative sedation. Median age was 76 years (IQR, 19), and 59 patients (52.2%) were men. An elastomeric infuser was used in 74 sedated patients (92.5%). Sedation duration had a median of 1 day (IQR, 2; range, 0–10). Symptom documentation was available for 56 sedated patients (70.0%); dyspnea was documented in 35 (62.5%), delirium in 19 (33.9%), and pain in 14 (25.0%). Symptoms could coexist. The median number of parenteral medications was 4 (IQR, 1). Conclusions: Palliative sedation was frequently used in this selected specialized home-care cohort and generally lasted a short period. The prevalence should not be generalized to other settings. Incomplete documentation and the retrospective, single-centre design limit interpretation. Prospective multi-centre studies are needed.
Related
- Symptom burden profiles and applied medication strategies in the days before and after initiation of palliative sedation in advanced cancer patients: an international prospective multicentre observational study (PALSED)
- Hemostatic Response to Palliative Radiotherapy for Bleeding Gastric Cancer and Pretreatment Endoscopic Characteristics: A Retrospective Cohort Study
- Assessing the Influence of Propofol Sedation Versus Propofol-Free Sedation on Recovery From Sepsis and Septic Shock in Mechanically Ventilated ICU Patients: A Retrospective, Propensity-Score Matched, Cohort Study
- Risk factors for venous thromboembolic events at 90 days in hospitalized patients with advanced cancer receiving palliative care: a multicenter retrospective cohort study
- Prevalence and Clinical Characteristics of Supernumerary Teeth in a Pediatric Clinical Population: A Retrospective Observational Study
BibTeX
@article{utrilla2026palliative,
title = {{Palliative Sedation at Home in Patients with Advanced Cancer: A Retrospective Observational Study of Clinical Characteristics and Sedation-Related Outcomes}},
author = {Salvador Martín Utrilla and Paula Oliver de Haro and Julián Mollá Marinas and Antonio Mancheño Álvaro and Enrique Jesús Sáez Álvarez},
journal = {Journal of Clinical Medicine},
year = {2026},
month = nov,
doi = {10.3390/jcm15218494},
url = {https://www.mdpi.com/2077-0383/15/21/8494},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Palliative Sedation at Home in Patients with Advanced Cancer: A Retrospective Observational Study of Clinical Characteristics and Sedation-Related Outcomes
AU - Salvador Martín Utrilla
AU - Paula Oliver de Haro
AU - Julián Mollá Marinas
AU - Antonio Mancheño Álvaro
AU - Enrique Jesús Sáez Álvarez
PY - 2026
DA - 2026/11/01
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15218494
UR - https://www.mdpi.com/2077-0383/15/21/8494
AB - Background/Objectives: Palliative sedation may relieve refractory suffering in patients with advanced cancer receiving end-of-life care at home. We aimed to describe patient characteristics, palliative sedation use, refractory symptoms, and sedation-related outcomes in a specialized hospital-at-home unit. Methods: We conducted a retrospective observational study of patients with advanced cancer who died during 2022 while receiving care from the Instituto Valenciano de Oncología hospital-at-home unit, Spain. Admission required clinical and social assessment confirming the need for hospital-level home care, feasibility of care at home, and adequate caregiver support. Sociodemographic, clinical, and sedation-related data were obtained from medical records. Analyses were descriptive and exploratory; associations were unadjusted. Results: The cohort included 113 patients; 80 (70.8%) received palliative sedation. Median age was 76 years (IQR, 19), and 59 patients (52.2%) were men. An elastomeric infuser was used in 74 sedated patients (92.5%). Sedation duration had a median of 1 day (IQR, 2; range, 0–10). Symptom documentation was available for 56 sedated patients (70.0%); dyspnea was documented in 35 (62.5%), delirium in 19 (33.9%), and pain in 14 (25.0%). Symptoms could coexist. The median number of parenteral medications was 4 (IQR, 1). Conclusions: Palliative sedation was frequently used in this selected specialized home-care cohort and generally lasted a short period. The prevalence should not be generalized to other settings. Incomplete documentation and the retrospective, single-centre design limit interpretation. Prospective multi-centre studies are needed.
SN - 2077-0383
ER -